Avidity Biosciences Announces Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax for Facioscapulohumeral Muscular Dystrophy at FSHD Society Congress

Reuters

2025/06/11

Avidity Biosciences Announces Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax for Facioscapulohumeral Muscular Dystrophy at FSHD Society Congress

Avidity Biosciences, Inc. (Nasdaq: RNA) has announced that it will present findings from its Phase 1/2 FORTITUDE™ trial at the 32nd Annual FSHD Society International Research Congress, scheduled for June 12-13, 2025, in Amsterdam, the Netherlands. The company will deliver two oral and one poster presentations. The trial evaluates delpacibart braxlosiran (del-brax), an Antibody Oligonucleotide Conjugate (AOC™), in adults with facioscapulohumeral muscular dystrophy (FSHD). Jeffrey M. Statland, M.D., of the University of Kansas Medical Center, will present the topline data from the dose escalation cohorts A and B on June 13, 2025. Additionally, Stephen Tapscott, M.D., Ph.D., of the Fred Hutchinson Cancer Center, will discuss a novel DUX4-regulated circulating biomarker in both oral and poster formats on June 12, 2025. The presentations and poster are accessible on Avidity's website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avidity Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA07811) on June 11, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2542582460"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542582460\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2542582460?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-11 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542582460","market":"nz","top_or_hot":-1,"title":"Avidity Biosciences Announces Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax for Facioscapulohumeral Muscular Dystrophy at FSHD Society Congress","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Avidity Biosciences Announces Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax for Facioscapulohumeral Muscular Dystrophy at FSHD Society Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/RNA\">Avidity Biosciences, Inc.</a> (Nasdaq: RNA) has announced that it will present findings from its Phase 1/2 FORTITUDE™ trial at the 32nd Annual FSHD Society International Research Congress, scheduled for June 12-13, 2025, in Amsterdam, the Netherlands. The company will deliver two oral and one poster presentations. The trial evaluates delpacibart braxlosiran (del-brax), an Antibody Oligonucleotide Conjugate (AOC™), in adults with facioscapulohumeral muscular dystrophy (FSHD). Jeffrey M. Statland, M.D., of the University of Kansas Medical Center, will present the topline data from the dose escalation cohorts A and B on June 13, 2025. Additionally, Stephen Tapscott, M.D., Ph.D., of the Fred Hutchinson Cancer Center, will discuss a novel DUX4-regulated circulating biomarker in both oral and poster formats on June 12, 2025. The presentations and poster are accessible on Avidity's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avidity Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA07811) on June 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Avidity Biosciences Announces Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax for Facioscapulohumeral Muscular Dystrophy at FSHD Society Congress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAvidity Biosciences Announces Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax for Facioscapulohumeral Muscular Dystrophy at FSHD Society Congress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-11 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Avidity Biosciences Announces Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax for Facioscapulohumeral Muscular Dystrophy at FSHD Society Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/RNA\">Avidity Biosciences, Inc.</a> (Nasdaq: RNA) has announced that it will present findings from its Phase 1/2 FORTITUDE™ trial at the 32nd Annual FSHD Society International Research Congress, scheduled for June 12-13, 2025, in Amsterdam, the Netherlands. The company will deliver two oral and one poster presentations. The trial evaluates delpacibart braxlosiran (del-brax), an Antibody Oligonucleotide Conjugate (AOC™), in adults with facioscapulohumeral muscular dystrophy (FSHD). Jeffrey M. Statland, M.D., of the University of Kansas Medical Center, will present the topline data from the dose escalation cohorts A and B on June 13, 2025. Additionally, Stephen Tapscott, M.D., Ph.D., of the Fred Hutchinson Cancer Center, will discuss a novel DUX4-regulated circulating biomarker in both oral and poster formats on June 12, 2025. The presentations and poster are accessible on Avidity's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avidity Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA07811) on June 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nNDL2nC696:1","article_id":"2542582460","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542582460","pubTimestamp":1749646838,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avidity Biosciences Inc. published the original content used to generate this news brief via PR Newswire  on June 11, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","BK4139":"生物科技","RNA":"Atrium Therapeutics"},"translate_title":"Avidity Biosciences在FSHD协会大会上公布了Del-brax治疗面肩肱肌营养不良症的1/2期FORTITUDE™试验的主要数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNA":0.9},"content_text":"Avidity Biosciences Announces Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax for Facioscapulohumeral Muscular Dystrophy at FSHD Society Congress\n    \n\nAvidity Biosciences, Inc. (Nasdaq: RNA) has announced that it will present findings from its Phase 1/2 FORTITUDE™ trial at the 32nd Annual FSHD Society International Research Congress, scheduled for June 12-13, 2025, in Amsterdam, the Netherlands. The company will deliver two oral and one poster presentations. The trial evaluates delpacibart braxlosiran (del-brax), an Antibody Oligonucleotide Conjugate (AOC™), in adults with facioscapulohumeral muscular dystrophy (FSHD). Jeffrey M. Statland, M.D., of the University of Kansas Medical Center, will present the topline data from the dose escalation cohorts A and B on June 13, 2025. Additionally, Stephen Tapscott, M.D., Ph.D., of the Fred Hutchinson Cancer Center, will discuss a novel DUX4-regulated circulating biomarker in both oral and poster formats on June 12, 2025. The presentations and poster are accessible on Avidity's website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avidity Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA07811) on June 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}